Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system and the integration of its U.S. commercial organization.

MarketBeat • May 9, 2026

Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results

Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update.

GlobeNewsWire • May 7, 2026

Senseonics Holdings (SENS) Reports Q1 Loss, Beats Revenue Estimates

Senseonics Holdings (SENS) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.4 per share a year ago.

Zacks Investment Research • May 7, 2026

Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of common stock were sold at a price to the public of $5.00 per share and the pre-funded warrants were sold at a purchase price of $4.999 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering were approximately $92.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Senseonics.

GlobeNewsWire • May 4, 2026

Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million

GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to transform lives in the global diabetes community, announced that it has entered into a Second Amendment to the Loan and Security Agreement with Hercules Capital, Inc. (NYSE: HTGC).

GlobeNewsWire • May 4, 2026

Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time

GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026.

GlobeNewsWire • May 1, 2026

Senseonics Shares Sink Friday: What's Driving The Move?

Shares of Senseonics Holdings Inc (NASDAQ:SENS) are trading sharply lower Friday morning following the late-Thursday announcement of the pricing for an $80 million underwritten public offering. Here's what investors need to know.

Benzinga • May 1, 2026

Senseonics Announces Commencement of $80 Million Public Offering of Common Stock and Pre-Funded Warrants

GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and, to certain investors, pre-funded warrants to purchase its common stock in lieu thereof. In connection with the proposed offering, Senseonics also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares offered in the public offering. All of the securities to be sold in the proposed offering will be offered by Senseonics. The pre-funded warrants will not be listed on any securities exchange.

GlobeNewsWire • Apr 30, 2026

Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants

GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $5.00 per share, and in lieu of common stock, to certain investors, pre-funded warrants to purchase 8,000,000 shares of common stock at a purchase price of $4.999 per pre-funded warrant share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $80 million. In addition, Senseonics granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2026, subject to satisfaction of customary closing conditions.   The pre-funded warrants will not be listed on any securities exchange.

GlobeNewsWire • May 1, 2026